Ind-swift Laboratories Share Price
Sector: Major Drugs
71.97 +0.67 (0.94%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
70.70
Today’s High
73.90
52 Week Low
67.15
52 Week High
186
71.91 +0.68 (0.95%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
71.30
Today’s High
74
52 Week Low
68.72
52 Week High
186
Key Metrics
- Market Cap (In Cr) 438.57
- Beta 0.4
- Div. Yield (%) 0
- P/B 0.45
- TTM P/E 1.81
- Peg Ratio 0.02
- Sector P/E 24.5
- Open Price 70.7
- Prev Close 71.3
Ind-swift Laboratories Analysis
Price Analysis
-
1 Week1.34%
-
3 Months-22.51%
-
6 Month-32.83%
-
YTD-34.39%
-
1 Year-36.26%
Risk Meter
- 53% Low risk
- 53% Moderate risk
- 53% Balanced Risk
- 53% High risk
- 53% Extreme risk
Ind-swift Laboratories News
Ind-Swift Laboratories Q3 FY24 Results Live: Profit Falls by 29.38% YOY
1 min read . 15 Feb 2024Ind-swift Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1280.9
- Selling/ General/ Admin Expenses Total
- 278.69
- Depreciation/ Amortization
- 53.26
- Other Operating Expenses Total
- -15.93
- Total Operating Expense
- 679.28
- Operating Income
- 601.62
- Net Income Before Taxes
- 581.76
- Net Income
- 420.96
- Diluted Normalized EPS
- 23.57
- Period
- 2024
- Total Assets
- 1165.11
- Total Liabilities
- 233.65
- Total Equity
- 931.46
- Tangible Book Valueper Share Common Eq
- 157.64
- Period
- 2024
- Cashfrom Operating Activities
- -181.32
- Cashfrom Investing Activities
- -104.32
- Cashfrom Financing Activities
- 698.91
- Net Changein Cash
- 413.28
- Period
- 2023
- Total Revenue
- 1207.31
- Selling/ General/ Admin Expenses Total
- 228.03
- Depreciation/ Amortization
- 57.08
- Other Operating Expenses Total
- -8.62
- Total Operating Expense
- 1053.5
- Operating Income
- 153.81
- Net Income Before Taxes
- 86.52
- Net Income
- 47.6
- Diluted Normalized EPS
- 10.55
- Period
- 2023
- Total Assets
- 1824.06
- Total Liabilities
- 1142.13
- Total Equity
- 681.93
- Tangible Book Valueper Share Common Eq
- 115.41
- Period
- 2023
- Cashfrom Operating Activities
- 194.62
- Cashfrom Investing Activities
- -13.37
- Cashfrom Financing Activities
- -185.66
- Net Changein Cash
- -4.41
- Period
- 2022
- Total Revenue
- 1038.73
- Selling/ General/ Admin Expenses Total
- 228.83
- Depreciation/ Amortization
- 131.04
- Other Operating Expenses Total
- -14.17
- Total Operating Expense
- 959.98
- Operating Income
- 78.76
- Net Income Before Taxes
- 12.53
- Net Income
- -2.15
- Diluted Normalized EPS
- -0.36
- Period
- 2022
- Total Assets
- 1800.79
- Total Liabilities
- 1199.82
- Total Equity
- 600.97
- Tangible Book Valueper Share Common Eq
- 101.54
- Period
- 2022
- Cashfrom Operating Activities
- 150.27
- Cashfrom Investing Activities
- 4.77
- Cashfrom Financing Activities
- -140.88
- Net Changein Cash
- 14.17
- Period
- 2021
- Total Revenue
- 891.34
- Selling/ General/ Admin Expenses Total
- 172.33
- Depreciation/ Amortization
- 87.01
- Other Operating Expenses Total
- -15.43
- Total Operating Expense
- 780.38
- Operating Income
- 110.96
- Net Income Before Taxes
- 18.01
- Net Income
- -3.15
- Diluted Normalized EPS
- -0.53
- Period
- 2021
- Total Assets
- 1818.45
- Total Liabilities
- 1214.94
- Total Equity
- 603.51
- Tangible Book Valueper Share Common Eq
- 100.55
- Period
- 2021
- Cashfrom Operating Activities
- 134.95
- Cashfrom Investing Activities
- -10.17
- Cashfrom Financing Activities
- -123.75
- Net Changein Cash
- 1.02
- Period
- 2020
- Total Revenue
- 779.64
- Selling/ General/ Admin Expenses Total
- 161.7
- Depreciation/ Amortization
- 89.83
- Other Operating Expenses Total
- -19.7
- Total Operating Expense
- 705.68
- Operating Income
- 73.96
- Net Income Before Taxes
- -19.77
- Net Income
- -21.19
- Diluted Normalized EPS
- -4.29
- Period
- 2020
- Total Assets
- 1870.01
- Total Liabilities
- 1229.37
- Total Equity
- 640.64
- Tangible Book Valueper Share Common Eq
- 101.47
- Period
- 2020
- Cashfrom Operating Activities
- 125.24
- Cashfrom Investing Activities
- -9.1
- Cashfrom Financing Activities
- -133.26
- Net Changein Cash
- -19.39
- Period
- 2019
- Total Revenue
- 756.6
- Selling/ General/ Admin Expenses Total
- 156.77
- Depreciation/ Amortization
- 104.05
- Other Operating Expenses Total
- -22.42
- Total Operating Expense
- 629.18
- Operating Income
- 127.43
- Net Income Before Taxes
- 49.68
- Net Income
- 28.95
- Diluted Normalized EPS
- -4.56
- Period
- 2019
- Total Assets
- 1923.96
- Total Liabilities
- 1336.15
- Total Equity
- 587.81
- Tangible Book Valueper Share Common Eq
- 107.56
- Period
- 2019
- Cashfrom Operating Activities
- -64.4
- Cashfrom Investing Activities
- -12.47
- Cashfrom Financing Activities
- 99.62
- Net Changein Cash
- 20.52
- Period
- 2024-12-31
- Total Revenue
- 8.66
- Selling/ General/ Admin Expenses Total
- 6.7
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 10.28
- Total Operating Expense
- 23.44
- Operating Income
- -14.78
- Net Income Before Taxes
- -1.08
- Net Income
- 0.01
- Diluted Normalized EPS
- 0
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 11.96
- Selling/ General/ Admin Expenses Total
- 5.8
- Depreciation/ Amortization
- 0.22
- Other Operating Expenses Total
- 9.63
- Total Operating Expense
- 23.97
- Operating Income
- -12.01
- Net Income Before Taxes
- 0.58
- Net Income
- 0.41
- Diluted Normalized EPS
- 0.07
- Period
- 2024-09-30
- Total Assets
- 1188.02
- Total Liabilities
- 176.47
- Total Equity
- 1011.55
- Tangible Book Valueper Share Common Eq
- 171.2
- Period
- 2024-09-30
- Cashfrom Operating Activities
- -23.37
- Cashfrom Investing Activities
- -48.55
- Cashfrom Financing Activities
- 78.27
- Net Changein Cash
- 6.35
- Period
- 2024-06-30
- Total Revenue
- 33.17
- Selling/ General/ Admin Expenses Total
- 6.09
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 9.51
- Total Operating Expense
- 43.16
- Operating Income
- -9.99
- Net Income Before Taxes
- 0.98
- Net Income
- 0.94
- Diluted Normalized EPS
- 0.16
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 393.33
- Selling/ General/ Admin Expenses Total
- 39.25
- Depreciation/ Amortization
- 12.67
- Other Operating Expenses Total
- 78.25
- Total Operating Expense
- -57.1
- Operating Income
- 450.44
- Net Income Before Taxes
- 487.16
- Net Income
- 352.64
- Diluted Normalized EPS
- 12.32
- Period
- 2024-03-31
- Total Assets
- 1165.11
- Total Liabilities
- 233.65
- Total Equity
- 931.46
- Tangible Book Valueper Share Common Eq
- 157.64
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -181.32
- Cashfrom Investing Activities
- -104.32
- Cashfrom Financing Activities
- 698.91
- Net Changein Cash
- 413.28
- Period
- 2023-12-31
- Total Revenue
- 287.51
- Selling/ General/ Admin Expenses Total
- 37.08
- Depreciation/ Amortization
- 13.56
- Other Operating Expenses Total
- 43.31
- Total Operating Expense
- 249.38
- Operating Income
- 38.13
- Net Income Before Taxes
- 24.19
- Net Income
- 19.42
- Diluted Normalized EPS
- 3.29
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Ind-swift Laboratories Technical
Moving Average
SMA
- 5 Day74.2
- 10 Day73.6
- 20 Day77.03
- 50 Day84.39
- 100 Day94.21
- 300 Day111.48
Ind-swift Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Jagsonpal Pharmaceuticals
- 213.5
- 0.4
- 0.19
- 328.02
- 109.42
- 1415.24
- Themis Medicare
- 174.85
- 25.45
- 17.03
- 313.65
- 115.05
- 1615.78
- Ind-swift Laboratories
- 71.97
- 0.67
- 0.94
- 186
- 67.15
- 438.57
- Brooks Laboratories
- 135
- -1.95
- -1.42
- 202.8
- 72.51
- 397.68
- Ambalal Sarabhai Enterprises
- 38.83
- -0.45
- -1.15
- 77.7
- 34.11
- 297.96
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Jagsonpal Pharmaceuticals
- 36.11
- 5.9
- 18
- 12.54
- Themis Medicare
- 32.01
- 3.68
- 18.03
- 14.96
- Ind-swift Laboratories
- 3.02
- 0.45
- 13.45
- 8.52
- Brooks Laboratories
- -
- 5.51
- -21.61
- -27.47
- Ambalal Sarabhai Enterprises
- 53.12
- 2.2
- 23.77
- 12.86
Ind-swift Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-Feb-25
- Quarterly Results
- 12-Feb-25
- Quarterly Results
- 11-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 27-Jun-24
- Preferential issue of shares
- 13-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 09-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 22-Feb-25
- 20-Jan-25
- COM
- 30-Sept-24
- 14-Aug-24
- AGM
- 22-Jul-24
- 28-Jun-24
- EGM
- 06-Oct-23
- 03-Oct-23
- EGM
- 30-Sept-23
- 31-Aug-23
- AGM
- 30-Sept-21
- 12-Aug-21
- AGM
- 28-Aug-21
- 06-Aug-21
- EGM



